Stockscreener 앱 받기
0.3599
5.85%
0.0199
시간 외 거래:
.36
0.000100
+0.03%
전일 마감가:
$0.34
열려 있는:
$0.34
하루 거래량:
447.59K
Relative Volume:
0.06
시가총액:
$16.47M
수익:
$16.77M
순이익/손실:
$-11.87M
주가수익비율:
-0.759
EPS:
-0.4742
순현금흐름:
$-5.90M
1주 성능:
-8.19%
1개월 성능:
+2.07%
6개월 성능:
-42.42%
1년 성능:
-75.18%
1일 변동 폭
$0.335
$0.3799
1주일 범위
$0.3161
$0.415
52주 변동 폭
$0.30
$1.48
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
IPA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
0.3599 | 16.47M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-10-25 | 개시 | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd 주식(IPA)의 최신 뉴스
HC Wainwright Has Positive Outlook of IPA FY2025 Earnings - Defense World
ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
HC Wainwright Has Bearish Forecast for IPA FY2028 Earnings - Defense World
ImmunoPrecise Antibodies’ (IPA) “Speculative Buy” Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Speculative Buy on Immunoprecise stock By Investing.com - Investing.com Australia
Benchmark maintains Speculative Buy on Immunoprecise stock - Investing.com India
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2025 Earnings Call Transcript - Insider Monkey
ImmunoPrecise Antibodies (NASDAQ:IPA) Price Target Lowered to $5.00 at HC Wainwright - Defense World
ImmunoPrecise Antibodies Earnings Call Highlights Growth - TipRanks
Immunoprecise stock target cut to $5 by H.C. Wainwright - Investing.com Australia
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates - MSN
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... By GuruFocus - Investing.com Canada
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlig - GuruFocus
ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024) - Yahoo
ImmunoPrecise Antibodies Reports Q3 FY25 Financial Results - TipRanks
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 - 01net
Immunoprecise Antibodies Ltd reports results for the quarter ended January 31Earnings Summary - TradingView
Immunoprecise Antibodies (IPA) Reports Financial Results And Recent Business Highlights For Third Quarter Fiscal Year 2025 - MarketScreener
IMMUNOPRECISE ANTIBODIES Earnings Results: $IPA Reports Quarterly Earnings - Nasdaq
ImmunoPrecise Secures Game-Changing $10M Deal as AI Division Reports 132% Growth - Stock Titan
A Look Ahead: ImmunoPrecise Antibodies's Earnings Forecast - Benzinga
IMMUNOPRECISE ANTIBODIES Earnings Preview: Recent $IPA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Immunoprecise Antibodies Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on Friday - Defense World
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates - MSN
ImmunoPrecise Antibodies’ (IPA) Buy Rating Reiterated at HC Wainwright - Defense World
ImmunoPrecise partners for cancer drug advancement By Investing.com - Investing.com Australia
What's Going On With ImmunoPrecise Stock Thursday?ImmunoPrecise Antibodies (NASDAQ:IPA) - Benzinga
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. - 01Net
Sector Update: Health Care -March 13, 2025 at 08:52 am EDT - Marketscreener.com
ImmunoPrecise Antibodies Signs Partnership Deal to Develop Cancer Treatments -March 13, 2025 at 07:55 am EDT - Marketscreener.com
ImmunoPrecise Antibodies Partners for $10M Cancer Therapeutics Development - TipRanks
Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock - Yahoo Finance
ImmunoPrecise partners for cancer drug advancement - Investing.com
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 - 01Net
ImmunoPrecise Q3 Earnings Postponed: Auditors Request Extra Time for Goodwill Review - StockTitan
ImmunoPrecise Antibodies Reschedules Q3 Financial Results Release - TipRanks
ImmunoPrecise Antibodies (IPA) to Release Earnings on Thursday - Defense World
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Short Interest Update - Defense World
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery - ACCESS Newswire
ImmunoPrecise Antibodies to Announce Q3 Fiscal 2025 Results - TipRanks
AI Antibody Pioneer ImmunoPrecise Sets March 13 Earnings CallWhat's Next for This Biotech Innovator? - StockTitan
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 - Yahoo Finance
ImmunoPrecise Antibodies Ltd. (IPA) Expands AI Leadership with Dr. Kamil Isaev Appointment - Insider Monkey
IPA and Ribopro form mRNA antibody discovery collaboration - Yahoo Finance
ImmunoPrecise Antibodies appoints Joseph Scheffler interim CFO - MSN
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy - 01Net
ImmunoPrecise & RIBOPRO Partner for AI-Powered Antibody Discovery - Contract Pharma
ImmunoPrecise Antibodies and RIBOPRO Partner to Revolutionize Antibody Discovery - TipRanks
ImmunoPrecise Antibodies annonce un remaniement de son équipe de direction - The Hastings Tribune
Immunoprecise Antibodies Ltd (IPA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):